81289-15-8

Basic information

• Product Name: 1-Methyl-1-thiophen-2-yl-ethylaMine
• Synonyms: 1-Methyl-1-thiophen-2-yl-ethylaMine;2-(Thiophen-2-yl)propan-2-aMine
• CAS NO: 81289-15-8
• Molecular Formula: C₇H₁₁NS
• Molecular Weight: 141.23394
• Mol File: 81289-15-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 207.023 °C at 760 mmHg
• Flash Point: 79.005 °C
• Appearance: /
• Density: 1.064 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-Methyl-1-thiophen-2-yl-ethylaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-1-thiophen-2-yl-ethylaMine(81289-15-8)
• EPA Substance Registry System: 1-Methyl-1-thiophen-2-yl-ethylaMine(81289-15-8)

Safety Data

• Hazardous Substances Data: 81289-15-8(Hazardous Substances Data)

Usage

General Description

1-Methyl-1-thiophen-2-yl-ethylamine, also known as MTEA, is a chemical compound with the molecular formula C9H13NS. It is a tertiary amine derivative with a thiophene ring containing a methyl group and an ethylamino group. MTEA is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also being studied for its potential applications in the field of medicinal chemistry, particularly in the development of new drugs for various medical conditions. MTEA has several important chemical properties, including its ability to form stable complexes with various metal ions and to act as a chelating agent in coordination chemistry. Overall, MTEA is a versatile compound with various potential uses in the field of organic and medicinal chemistry.

Upstream product

• 1003-31-2 thiophene-2-carbonitrile 
• 917-54-4 methyllithium 

Relevant articles and documents

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.